|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.57|
|Dividend & Yield||1.03 (3.27%)|
|1y Target Est||N/A|
The pharma company reformulated a cancer drug to treat MS and jacked up the price.
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
Diabetes accounts for nearly 10% of US health care spending